

1 **Predictors of Postviral Symptoms Following Epstein-Barr Virus-Associated Infectious**
2 **Mononucleosis in Young People – Data from the IMMUC Study**

3
4 Maren Bodenhausen^{1*}, Jonas Geisberger^{1*}, Julia Lange de Luna¹, Johannes Wendl^{2,3},
5 Alexander Hapfelmeier^{2,3}, Lina Schulte-Hillen¹, Rafael Pricoco^{1,17}, Nina Körber^{4,5,6}, Tanja
6 Bauer^{4,5,6}, Josef Mautner^{1,5,6}, Dieter Hoffmann^{4,6}, Peter Lupp^{6,7}, Silvia Egert-Schwender⁸,
7 Elfriede Nößner^{5,6}, Henri-Jacques Delecluse^{6,9}, Susanne Delecluse^{6,9}, Fabian Hauck^{6,10},
8 Christine Falk^{6,11}, Thomas Schulz^{6,12,16}, Marc-Matthias Steinborn¹³, Andreas Bietenbeck¹⁴,
9 Alexandra Nieters^{6,15}, Lorenz Mihatsch^{1**}, Katrin Gerrer^{1**}, Uta Behrends^{1,5,6**}; for the IMMUC
10 Study Group***

11
12 ¹ MRI Chronic Fatigue center for Young People, Children's Hospital Schwabing, TUM School
13 of Medicine and Health, Technical University of Munich (TUM), Munich, Germany

14 ² Institute of General Practice and Health Services Research, TUM School of Medicine and
15 Health, TUM, Munich, Germany

16 ³ Institute of AI and Informatics in Medicine, TUM School of Medicine and Health, TUM,
17 Munich, Germany

18 ⁴ Institute of Virology, TUM School of Medicine and Health, TUM, Munich, Germany

19 ⁵ Helmholtz Center Munich (HMGU), Munich, Germany

20 ⁶ German Center for Infection Research (DZIF), Germany

21 ⁷ Institute of Clinical Chemistry and Pathobiochemistry, TUM, Munich, Germany

22 ⁸ Münchner Studienzentrum (MSZ), TUM, Munich, Germany

23 ⁹ German Cancer Research Center (DKFZ), F100, Heidelberg, Germany

24 ¹⁰ Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität, Munich, Germany

25 ¹¹ Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany

26 ¹² Institute of Virology, Medical School, Hannover, Germany

27 ¹³ Department of Pediatric Radiology, Munich Municipal Hospital Group Schwabing, Munich,
28 Germany

29 ¹⁴ MVZ Labor Poing, Munich, Germany

30 ¹⁵ Center for Chronic Immunodeficiency (CCI), Freiburg, Germany

31 ¹⁶ Cluster of Excellence 2155 RESIST

32 ¹⁷ Institute of Medical Immunology, Charité, Berlin, Germany

33

34 * Bodenhausen M and Geisberger J contributed equally to this manuscript.

35 ** Behrends U, Gerrer K, and Mihatsch L contributed equally to this manuscript.

36 *** IMMUC Study Group team members are listed in the Acknowledgments.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37

38 **Keywords:** Epstein-Barr virus, disease score, protraction, risk factor, fatigue

39 **Running title:** Predictors of Postviral Symptoms Following Epstein-Barr Virus-Associated
40 Infectious Mononucleosis in Young People – Data from the IMMUC Study

41

42 **Corresponding author:**

43 Uta Behrends, M.D.

44 Children's Hospital

45 TUM School of Medicine and Health, Technical University of Munich,

46 Koelner Platz 1, 80804 Munich, Germany

47 Phone: +49 89 3068 2793

48 Fax: +49 89 3068 3800

49 E-mail: uta.behrends@mri.tum.de

50

51 **Highlights:**

- 52
- 53 • Severe gastrointestinal symptoms are associated with protracted course of Epstein-
54 Barr virus-associated Infectious Mononucleosis (EBV-IM).
 - 55 • Signs of immune dysregulation prior to EBV-IM can indicate an increased risk of
56 protracted symptoms.
 - 57 • Greater number of initial symptoms helps to identify patients developing postviral
58 fatigue.

58

59 **Planned Journal:** Journal of Clinical Virology (J. Clin. Virol.)

60 **Number of characters/spaces of the title:** 141 (max. not defined)

61 **Number of key words:** 5 (max. not defined, usually 3-5)

62 **Number of words (abstract):** 250 (max. 250)

63 **Number of words (manuscript):** 2459 (max. 2500)

64 **Number of references:** 38 (max. 40)

65 **Number of figures:** 5

66 **Number of tables:** 2

67 **Number of supplementary tables:** 2

68 **Number of supplementary figures:** 3

69 **Number of supplementary materials:** 2

70

71 **ABSTRACT** (250/250 words)

72 **Background.** Epstein-Barr virus-associated Infectious Mononucleosis (EBV-IM) is a common
73 disease following primary EBV infection in children and adolescents. While EBV-IM is mostly
74 self-limiting, symptoms like fatigue may persist over several months or even result in myalgic
75 encephalomyelitis/chronic fatigue syndrome (ME/CFS). This large clinical observational study
76 aimed at identifying risk factors for protracted courses of EBV-IM in young people.

77 **Methods.** A cohort of N=200 children, adolescents, and young adults with acute primary EBV
78 infection was recruited from hospitals and private practices. Data on the patients' medical
79 history as well as clinical and laboratory parameters were collected at a baseline visit (V1)
80 within four weeks after symptom onset (T_{onset}) and at two follow-up visits (V2 and V3) one and
81 six months after T_{onset} . Risk factors for protracted symptoms at V3 were modeled using
82 multivariable logistic regressions.

83 **Results.** Protracted symptoms were observed in 55/183 (30.1%) and protracted fatigue in
84 34/181 (18.8%) patients at V3. A medical history indicating an increased susceptibility to
85 infectious diseases as well as distinct severe IM symptoms, e.g. severe gastrointestinal
86 symptoms, were significantly associated with protracted disease [OR: 2.31; P=0.011 and OR:
87 3.42; P=0.027] and with chronic fatigue [OR: 2.98; P=0.006 and OR: 3.54; P=0.034],
88 respectively. Occurrence of twelve or more clinical and laboratory parameters until and
89 including V1 discriminated between fatigue and no fatigue at V3 [OR 2.43, P=0.033].

90 **Conclusion.** A clinical history of immune dysregulation as well as distinct severe IM symptoms
91 might predict protracted post-viral disease and thus help in the identification of young patients
92 at risk.

93 **INTRODUCTION**

94 Infectious mononucleosis (IM) develops in up to 75% of adolescents and young adults after
95 primary infection with Epstein-Barr virus (EBV) [1]. Symptoms typically include fever,
96 lymphadenopathy, tonsillopharyngitis, splenomegaly, and fatigue, and usually are self-limiting
97 within two weeks to three months [1]. However, acute complications such as kissing tonsils,
98 splenic rupture, or life-threatening hemophagocytic lymphohistiocytosis (HLH) [1, 2] can occur,
99 and lymphoproliferative disease can manifest in immunocompromised patients [3]. Moreover,
100 post-viral symptoms may persist for weeks or years and may fulfill the clinical criteria of myalgic
101 encephalomyelitis/chronic fatigue syndrome (ME/CFS) [4, 5], significantly compromising daily
102 activities [6].

103 Risk factors for long-term IM sequelae are still under investigation, and various scores have
104 been published to assess IM severity, complexity, and protraction [7-13]. In a large cohort of
105 college students, physical symptoms and immune dysregulation have been identified as risk
106 factors for ME/CFS following IM [14], and autonomic symptoms along with distinct immune
107 markers were suggested as predictors of severe ME/CFS [15].

108 Here, we report on a novel IM scoring system and on candidate risk factors for protracted
109 symptoms identified in the Munich Infectious Mononucleosis (IMMUC) study. This
110 observational, prospective, longitudinal study investigates a comprehensive set of routine and
111 experimental data in 200 children, adolescents, and young adults with recent IM to identify
112 biomarkers and causative factors of complicated disease trajectories, including chronic fatigue.

113 MATERIAL & METHODS

114 **Ethics, Study Setting, and Inclusion Criteria:** The IMMUC study was approved by the TUM
115 University Hospital Ethics Committee (No. 112/14) and adheres to the 1964 Declaration of
116 Helsinki, its later amendments, and the ICH-GCP regulations. All participants and/or legal
117 guardians gave written informed consent. The study was registered at ClinicalTrials.gov
118 ([NCT06002802](https://clinicaltrials.gov/ct2/show/study/NCT06002802)). 200 participants with recent IM onset were prospectively recruited from
119 hospitals or private practices in or around Munich between February 2016 and June 2019 and
120 observed up to 12 months after IM onset. General, clinical, and virological inclusion criteria are
121 summarized in **Tab. 1**.

122 **Study Visits, Study Periods and Study Data:** Patients were seen at visit 1 (V1) within 28
123 days after onset (DAO) of IM (DAO 0= T_{onset}). V2 was scheduled at four to six weeks after T_{onset}
124 and V3 at four to 12 months after T_{onset} . A defined set of virological (IM_{Vir}), clinical chemistry
125 (IM_{Lab}), and clinical (IM_{Clin}) features of IM was investigated at each visit. Additionally, medical
126 history data and external laboratory data were collected for the time periods before T_{onset} and
127 between T_{onset} , V1, and V2, to generate combined datasets for the history period (HP) before
128 T_{onset} , the very early period (VEP) from T_{onset} up to and including V1, and the early period (EP)
129 from T_{onset} up to and including V2 (**Fig. 1**). All visits included a structured interview, a physical
130 examination, and peripheral blood collection for routine (reported here) and experimental
131 (reported elsewhere) laboratory analyses. Splenic sonography was performed at V1 and V2
132 and in case of persistent splenomegaly at V3. For a detailed account of the collected study
133 data see **Suppl. Methods, Suppl. Material M1, and Suppl. Material M2**.

134 **IM Scoring:** A score was developed to grade severity (S_{max}), complexity (C_{max}), and
135 protraction of individual IM features and overall IM at each visit and for each period (**Tab. 2**).
136 Up to five grades of severity (S0-5) were evaluated for each IM feature, and the highest severity
137 grade of all distinct features was used to grade the overall IM (**Suppl. Mat. M2**). By calculating
138 the number of IM features, complexity grades were determined for the overall IM (C0-C23),
139 IM_{Clin} (C0-15), and IM_{Lab} (C0-8) IM. Protraction grades were defined as P0 (feature/IM not
140 present anymore at V2 and V3), P1 (feature/IM present at V2 but not at V3), or P2 (feature/IM
141 present at V3). Since the clinical significance of mild lymphadenopathy and splenomegaly at
142 V3 was unclear, only S2-4 of the latter at V3 were counted as P2. The grading of fatigue at V3
143 differed from that at V1 and V2 due to an increasing clinical impact of fatigue over time.

144 **Outcome Measures, Predictor Variables in Multivariable Logistic Regression Models:**
145 Long-term IM protraction (P2-IM vs. P0/1-IM) or chronic fatigue (P2-fatigue vs. P0/1-fatigue)
146 were the binary outcome measures to be modelled. Predictor variables were either measured
147 repetitively at visits V1 and V2 (quantitative and categorized IM_{Vir} , IM_{Lab} and IM_{Clin} features)
148 and thus, included into the *visit-dependent* analyses (see below) or only once during the

149 periods HP, VEP, and/or EP (quantitative and categorized baseline patient characteristics as
150 well as Cmax-IM, -IM_{Lab}, -IM_{Clin}, Smax-IM, -IM_{Lab}, and -IM_{Clin} features) and thus included into
151 the *period-dependent* analyses (see below).

152 **Sample Size Calculation:** We expected approximately 10% of patients with P2-IM, and
153 therefore, set the sample size to N=200 patients (**Suppl. Methods**).

154 **Visit-Dependent Analyses:** Each multivariable logistic regression model included one of the
155 predictor variables measured at V1 and V2, and sex and age as independent variables. Since
156 individual patients were measured repetitively, an interaction effect between the predictor
157 variable and DAO was included in each model. The effect of a predictor variable can thus be
158 described in dependence on DAO. These models also determined a time interval at which the
159 OR of the predictor variable was significantly different from 1. The robust Huber-White
160 estimator accounted for minor misspecifications of the model assumption due to repeated
161 measurements.

162 **Period-Dependent Analyses:** Each multivariable logistic regression model included one of
163 the predictor variables measured once for either of the three periods: HP, VEP, or EP, and sex
164 and age as independent variables. A grid search was used to find the optimal cut-off value for
165 Cmax-IM and Cmax-IM_{clin} in terms of the area under the curve (AUC).

166 For the *visit-* and *period-*dependent analyses, models with less than five observations per
167 independent variable per category variable of the outcome variable were discarded to prevent
168 overfitting. Only significant results are presented here due to the abundance of variables
169 investigated.

170 **Other Statistical Analyses:** Hypothesis tests were performed at exploratory 5% significance
171 levels. P-values are exploratory and thus not corrected for multiple testing . Analyses were
172 performed using R, version 4.1.3 (The R Foundation for Statistical Computing, Vienna, Austria)
173 [16].

174

175

176

177

178

179

180

181 RESULTS

182 Of 200 study participants assessed at V1, 194 and 183 attended V2 and V3, respectively (**Fig.**
183 **1A**). Study visits (V1, V2, V3) and study periods (HP, VEP, EP) are depicted in **Fig. 1B**.

184 **Baseline Patient Characteristics:** Detailed data are shown in **Suppl. Table S1A to S1F**. The
185 cohort included 92 children (1-11 years), 84 adolescents (12-17 years), and 24 adults (18-33
186 years). 54.5% patients were female. The mean age was 11.99 ± 6.08 years (range: 1–33) (male:
187 11.76 ± 6.89 , female: 12.18 ± 5.33 ; t-test: $P=0.632$). A history of increased susceptibility to
188 infections and/or immune dysregulation (ELVIS and/or GARFIELD criteria [17]) prior to IM was
189 reported by 47.5% of patients (**Suppl. Table 1E**). When asked for any fever or antibiotic
190 therapy during the six months prior to IM, 37.0% and 13.6% of patients provided positive
191 answers, respectively. 35.7% and 6.0% of patients remembered ≥ 1 or ≥ 2 family members with
192 a history of IM.

193 **Virological Features of IM:** Detailed data are provided in **Fig. 2**.

194 **Severity, Complexity, and Protraction of IM:** Comprehensive data on IM severity,
195 complexity, and protraction are provided in **Fig. 3A-C**, **Suppl. Fig. S1**, **Suppl. Fig. S2** and
196 **Suppl. Tab. S2**. IM severity and complexity decreased from V1 to V3 as expected. At least
197 one IM feature persisted in 52.3% at V2 (P1) and in 27.9 % at V3 (P2) (**Fig. 3C**). 34 (18.8%)
198 patients suffered from fatigue at V3, with mild fatigue (S1)-reported by 82.4% and moderate
199 fatigue (S2) (“reduced education/work/club sports”) by 17.6% of these patients (**Fig. 3A,C**).

200 **Predictors for Long-Term Protraction (P2-IM):**

201 Significant predictors of any IM feature at V3 (P2-IM) of the *visit*-dependent analyses are
202 shown in **Fig. 4A**. Early positivity for VCAp18 IgG was the only risk factor, with decreasing
203 effect over time (negative slope in **Fig. 4A**). Protective effects were also observed for early
204 atypical lymphocytosis (until 6 DAO), tonsillopharyngitis (until 9 DAO) and leukocytosis (until
205 4 DAO). Complexity of IM and IM_{Clin} were significant risk factors for P2-IM from DAO=6 and
206 DAO=5 onwards, respectively. Additional IM_{Clin} features predicted P2-IM, again with a delay of
207 few days after T_{onset} and depending on severity (positive slope in **Fig. 4A**). Considering the
208 AUC, the best predictor variables were complexity of IM_{Clin} (AUC 0.68), complexity of IM (AUC
209 0.66) and presence of other airway symptoms [S1-4 vs. S0] (AUC 0.62).

210 Significant predictors of any IM feature at V3 (P2-IM) of the *period*-dependent analyses are
211 shown in **Fig. 5A**. IM_{Clin} complexity in the VEP and EP were the best predictors in terms of the
212 AUC. The ROC analysis indicated that a cut-off of ≥ 10 and ≥ 9 IM_{Clin} features during the VEP
213 (OR 2.61, 95%-CI: [1.27, 5.37]) and EP (OR 2.63, 95%-CI: [1.37, 5.03]) provided the greatest
214 AUCs for predicting P2-IM, respectively. Analogously, a cut-off of ≥ 12 and ≥ 13 IM features
215 provided the greatest AUCs for the VEP (OR 2.47, 95%-CI: [1.26, 4.87]) and EP (OR 2.99,

216 95%-CI: [1.49, 5.98]), respectively. Interestingly, ≥ 1 positive ELVIS criterion was also identified
217 as a significant risk factor for P2-IM.

218 ***Predictors for Chronic Fatigue (P2-fatigue):***

219 Significant predictors of fatigue at V3 (P2-fatigue) of the *visit*-dependent analyses are shown
220 in **Fig. 4B**. Fatigue was the most frequent IM feature at V3 (**Suppl. Fig. S3E**). It was, therefore,
221 not unexpected to find overlaps between predictors for P2-fatigue and P2-IM. The best
222 predictor for P2-fatigue regarding AUC was other airway symptoms which were significant risk
223 factors after DAO 17, with subsequent OR increase over time. Moreover, moderate to severe
224 GI symptoms and VCAp18 IgG detection in immunoblots were significant predictors with an
225 increasing and decreasing OR over time, respectively (**Fig. 4B**). We did not find a significant
226 *visit*-dependent effect of (very) early fatigue for P2-fatigue.

227 Significant predictors of fatigue at V3 (P2-fatigue) of the *period*-dependent analyses are shown
228 in **Fig. 5B**. Early exanthema, early musculoskeletal symptoms, and ≥ 8 minor infections per
229 year (ELVIS criterion) prior to IM significantly predicted P2-fatigue. Early IM_{Clin} complexity was
230 the best predictor (AUC 0.74) of the *period*-dependent analyses. ROC analysis indicated that
231 a cut-off of ≥ 12 IM features in the VEP (OR 2.43, 95%-CI: [1.07, 5.49]), and of ≥ 11 features in
232 the EP (OR 3.39, 95%-CI: [1.41, 8.17]), as well as ≥ 9 IM_{Clin} features in both periods (VEP: OR
233 2.47, 95%-CI: [1.14, 5.33]; EP: OR 4.41, 95%-CI: [1.90, 10.21]) resulted in the greatest AUC
234 for predicting fatigue at V3 (P2-fatigue), respectively. Early fatigue was not a significant
235 predictor of P2-fatigue.

236 DISCUSSION

237 Long-term sequelae of IM, such as chronic fatigue, manifest in a significant number of cases
238 [19, 20] and hit young people in a very vulnerable stage of their lives, indicating a high medical
239 need for research on risk factors, prevention, and therapeutic strategies [18, 19]. To identify
240 biomarkers and predictors of acute and long-term IM complications we implemented the
241 longitudinal IMMUC study and report here on the first results from a cohort of 200 pediatric
242 and young adult patients.

243 In line with published data, 72.1% of the patients had fully recovered five to eight months after
244 IM onset [14]. Remarkably, 27.9% of the study participants showed protracted disease for
245 more than four months after IM onset, including 18.8% cases with chronic fatigue. Several
246 clinical and laboratory parameters were identified that may predict protracted IM and thus
247 identify patients at risk.

248 Of note, IM complexity was a significant predictor of long-term protraction. Within the VEP and
249 EP, 50.5% and 94% study participants presented with maximum IM complexity. Ten or more
250 very early IM_{Clin} features predicted protracted disease at V3 and nine or more predicted chronic
251 fatigue. (Very) early IM_{Lab} features did not add any essential value to prediction accuracy.

252 Our findings are consistent with those reported by Cervia and colleagues, who identified the
253 complexity of coronavirus disease 2019 (COVID-19) in combination with other clinical and
254 laboratory characteristics as risk factors for post-acute COVID-19 syndromes [20]. It was
255 hypothesized that a greater number of symptoms during the acute infection, including
256 autonomic dysregulation, might reflect an initial immune (over)activation that results in
257 prolonged impaired health [15, 21]. Our results are also in line with reports indicating an
258 increased risk of ME/CFS in patients with more or more severe physical symptoms during the
259 acute infection [13, 14].

260 Patients with distinct inborn errors of immunity (IEI) carry an increased susceptibility to EBV-
261 associated HLH or lymphoproliferative disorders [3]. However, little is known about clinical IEI
262 warning signs as possible predictors of protracted IM. In a previous study, 60% of ME/CFS
263 patients reported a history of recurrent infections [22]. Our IMMUC data demonstrate that ≥ 1
264 major infection and ≥ 8 minor infections per year predicted any IM feature or fatigue at V3,
265 respectively. These findings suggest that patients with an increased susceptibility to infection
266 should be closely monitored and offered timely advice after IM diagnosis.

267 In addition, chronic fatigue was predicted by (very) early exanthema and facial edema, possibly
268 indicative of IM-associated vascular inflammation [23-25], and was associated with early
269 musculoskeletal symptoms and (very) early moderate to severe GI symptoms. Interestingly,
270 GI symptoms prior to IM have been associated with the development of ME/CFS [15]. Taken

271 together, these findings suggest that preexisting or early autonomic symptoms in the context
272 of IM might predict post-viral disease.

273 Remarkably, the detection of EBV VCAp18 IgG considered a late marker of primary EBV
274 infection [26], was identified as a significant predictor of any long-term protraction when
275 detected within the first three weeks after IM onset. This might indicate that individuals with a
276 long EBV incubation period prior to IM may face an increased risk of protracted disease, and
277 early immunoblot analysis might help in prediction. Early detection of EBV VCAp18 IgG has
278 been associated with a lower IM severity score by others but was not investigated as a
279 predictor of protracted disease [27]. Moreover, EBV VCAp18 IgM-mediated complement
280 deposition and EBV VCAp18 IgG-dependent cellular phagocytosis were positively associated
281 with IM severity [28], and complement activation was discussed in ME/CFS-associated
282 immune dysregulation [22].

283 **Limitations.** First, the results of the IMMUC scores might have been prone to interviewer bias.
284 Second, most patients were recruited when initial IM symptoms had declined. Therefore,
285 laboratory parameters at V1 may reflect a subacute stage of IM and remembered IM symptoms
286 of the VEP might be influenced by recall bias. Third, the time period between V1 and follow-
287 up visits varied to match best with school schedules and family plans.

288
289 **Conclusion.** In this IMMUC study, we implemented a novel scoring system to evaluate IM
290 severity, complexity, and protraction and identified several candidate predictors of chronic
291 postviral disease that are easily assessed during routine diagnostics. This score may help
292 identifying patients at risk and facilitate prompt medical provisioning. In addition, this score
293 forms the basis for the analysis of diverse immunological parameters investigated in this cohort
294 that might further improve prediction for long-term sequelae in young people with IM.

295 **NOTES**

296 **Acknowledgments.** The authors would like to thank the IMMUC Study Group team members
297 F. Fischer, M. Burggraf, P. Wallraven, R. Weggel, K. Bartl, L. Werny, K. Rautter, T. Hofberger,
298 Y. Müller, H. Zietemann, E. Planatscher, J. Nüchel, K. Michel, S. Strunz., J. Mücke, K.
299 Mittelstraß, M. Bach, F. Martin, L. Kramer, C. Richter, A. Yardim, and L. Beckert for their great
300 study assistance. Furthermore we would like to thank patients and their families for
301 participating in the study, as well as all participating physicians for announcing the study and
302 transferring interested patients. Without their tremendous support this work would have not
303 been possible.

304 **Author contributions.** U.B. acquired funding, supervised and coordinated the study together
305 with K.G., U.B., M.B., J.G., A.H., S.S, N.K., T.B., J.M, D.H., P.L., S.E-S., H-J.D., S.D., F.H.,
306 C.F., T.S., M-M.S., A.B., and K.G. designed the study. M.B., J.G., L.S-H., R.P., F.H., C.F., M-
307 M.S., A.B., K.G., and U.B. recruited and visited the patients and acquired the data. M.B., J.G.,
308 J.L.L., J.W., A.H., E.N., F.H., M-M.S., A.B., A.N., L.M., K.G., and U.B. analysed and interpreted
309 the data. M.B., J.G., L.M., J.L.L., A.H., A.N., K.G., and U.B. wrote the first version of the
310 manuscript. All authors read, edited, and commented on the draft. All authors approved the
311 final version of the manuscript to be published and agreed to be accountable for all aspects of
312 the work in ensuring that questions related to the accuracy or integrity of any part of the work
313 are appropriately investigated and resolved.

314 **Availability of data and materials.** M.B., J.G., L.M., J.L.L., A.H., J.W., K.G., and U.B. have
315 full access to all data and take responsibility for their integrity and accuracy.

316 **Ethical considerations.** The IMMUC study was approved by the Ethics Committee of the
317 School of Medicine and Health of the Technical University of Munich (reference number:
318 112/14).

319 **Funding.** This work was funded by the German Center of Infection Research (DZIF) (grant
320 numbers 07_905 and 07_909). Funding was acquired by U.B. and received by P.L., S.E-S.,
321 A.H., D.H., F.H., J.M., T.B., H-J.D., C.F., and T.S..

322 **Potential conflicts of interest.** A.B. received lecture fees from Siemens. U.B. received
323 research grants for ME/CFS or EBV studies from the Federal Ministry of Education and
324 Research, the Federal Ministry of Health, the Bavarian State Ministry of Health and Care, the
325 Bavarian State Ministry of Science and the Arts, the German Center for Infection Research,
326 the People for Children (Menschen für Kinder) foundation, the Weidenhammer-Zoebele
327 Foundation, the Lost Voices Foundation, and the ME/CFS research foundation. All other
328 authors have no conflict of interest to declare.

Table 1. IMMUC Inclusion Criteria

A) General Criteria	
I	Age ≤ 39 years
II	No pregnancy ≤ 12 months prior to recruitment
III	Written informed consent
B) Clinical IM Criteria	
At least 1 of the following IM symptoms with new onset ≤ 28 days prior to recruitment	
I	Tonsillopharyngitis
II	Lymphadenopathy
III	Fever ≥ 38.5°C
IV	Fatigue
C) Virological IM Criteria	
At least 1 of I.1-4 at V1 <u>and</u> II at V1 <u>and</u> III at V1 or Tonset <u>and</u> IV	
I	1. EBV DNA positive in cell fraction 2. EBV DNA positive in plasma 3. EBV VCA IgM positive in any test 4. EBV VCA IgG positive in any test
II	EBNA-1 IgG maximal 1+ in immunoblot
III	EBNA-1 IgG negative in any test
IV	All data Tonset-V3 support EBV primary infection

Table 2. IMMUC Scores

Severity of IM Features or IM	
S0-5	0 = not present 1 = very mild 2 = mild 3 = severe 4 = very severe 5 = associated with death due to IM
Complexity of Clinical or Laboratory IM Features or IM	
C1-23	Defined as the number of IM features present
Protraction of IM Features or IM	
P0-2	0 = not present at V2 or V3 1 = present at V2 but not V3 or unknown at V3 2 = present at V3

SUPPLEMENTARY METHODS

Study Data: Baseline patient characteristics included age, sex, body mass index (BMI), body height, serum titers (anti-diphtheria and anti-tetanus toxoid IgG, total IgA, IgM, IgG, IgE, vitamin D), and data from the general medical history of patients and families (**Suppl. Tab. 1**). The patient's medical history addressed clinical signs of pathological susceptibility to infections (ELVIS) [17] and immune dysregulation (GARFIELD) [17], failure to thrive, developmental delay, vaccination status, infectious diseases (influenza, herpes labialis, varicella, measles), allergies, asthma, cancer, transplantation, transfusions, exposure to farm animals, as well as specific events within 6 months before T_{onset} (fever, use of antibiotics/analgesics/antiphlogistics, traveling to certain regions). The family's medical history addressed parent consanguinity, the number of siblings in the same household, as well as a history of IM, known inborn errors of immunity (IEI), cancer, neurodermatitis, autoimmune disease, allergies, and/or asthma (**Suppl. Mat. M1**). IM_{Clin} features included fever, fatigue, lymphadenopathy, tonsillopharyngitis, splenomegaly, facial edema, exanthema, other airway symptoms, other gastrointestinal (GI) symptoms, urogenital symptoms, bleeding and/or treatment for bleeding or anemia, neurological symptoms, musculoskeletal symptoms, hospitalization, and treatment for HLH (**Suppl. Mat. M2**); they were evaluated retrospectively and prospectively from T_{onset} until V3. IM_{Lab} features included lymphocytosis, neutropenia, anemia, thrombocytopenia, hyperferritinemia, hepatitis, nephropathy, and CRP elevation defined by age-adapted cut-off levels of blood count, transaminases (ASAT, ALAT), CRP, ferritin, creatinine, and (cystatin C if creatinine levels were elevated) in serum. IM_{Vir} features included EBV DNA in plasma (EBV_{Plasma}), cell fraction (EBV_{cells}), and oral washes (EBV_{oral}) evaluated by PCR (TaqMan™ 7500, Thermo Fisher Scientific, Waltham, USA), as well as anti-EBV VCA IgM, anti-EBV VCA IgG, and anti-EBNA-1 IgG determined in serum by CMIA [ARCHITECT i1000SR™, Abbot Laboratories, Chicago, USA]), and serum IgG against EA_{p54}, EA_{p138}, VCA_{p18}, VCA_{p23}, BZLF1 or EBNA-1 detected by immunoblot (ProfiBlot™, Tecan Group Ltd., Männedorf, Switzerland).

Sample Size Calculation: With 20 expected P2 cases and a required minimum number of 5-10 observations in the less frequent outcome class, we could consistently estimate multivariable logistic regression models with 2-4 parameters [31, 32]. An unpaired two-sided t-test with a 5% significance level has 80% power to detect an effect size of 0.7 when the sample sizes in two groups are N=18 (P2) and N=180 (P0-1) in a total sample size of N=198, as expected (nQuery Advisor 7.0).

SUPPLEMENTARY TABLES

Supplementary Table S1A. *Baseline Patient Characteristics – Sex and Age Distribution at Recruitment*

Sex	Number/Total (%)
Male	91/200 (45.5%)
Female	109/200 (54.5%)
Age Groups	Number/Total (%)
Children 0-11 years	92/200 (46.0%)
Adolescents 12-17 years	84/200 (42.0%)
Adults 18-39 years	24/200 (12.0%)

Supplementary Table S1B. *Baseline Patient Characteristics – Body Measures and Serum Titers*

Characteristics	Number/Total (%)		
	Below Normal Range	Within Normal Range	Above Normal Range
Body height [1]	4/198 (2.0%)	182/198 (91.9%)	12/198 (6.1%)
Body mass index (BMI) [1]	9/200 (4.5%)	188/200 (94.0%)	3/200 (1.5%)
Vitamin D [2]	68/200 (34.0%)	132/200 (66.0%)	0/200 (0.0%)
Total IgE [2]	n/a	111/200 (55.5%)	89/200 (44.5%)
Total IgA [2]	0/200 (0.0%)	156/200 (78.0%)	44/200 (22.0%)
Total IgM [2]	3/200 (1.5%)	129/200 (64.5%)	68/200 (34.0%)
Total IgG [2]	3/200 (1.5%)	162/200 (81.0%)	35/200 (17.5%)
Anti-Diphtheria toxoid IgG [3]	0/200 (0.0%)	200/200 (100.0%)	n/a
Anti-Tetanus toxoid IgG [3]	8/200 (4%)	192/200 (96.0%)	n/a
Magnesium [2]	0/170 (0.0%)	143/170 (84.1%)	27/170 (15.9%)

n/a: not applicable

[1] Age-adapted normal range of body measures (3th – 97th percentile) [33-35]

[2] Normal range vitamin D serum, total immunoglobulins (Ig) (5th – 95th percentile) and magnesium serum [36]

[3] Normal range of vaccination titers according to the information of the standing committee on vaccination (STIKO) at the Robert Koch Institute (RKI), a department of the German Federal Health Agency [37], accessed on February 6th, 2024.

Supplementary Table S1C. Baseline Patient Characteristics – General Medical History

Vaccination Status	Number/Total (%)
Complete vaccination status [4]	177/199 (88.9%)
Incomplete vaccination status [4]	22/199 (11.1%)
Specific Infectious Diseases	Number/Total (%)
Herpes labialis	9/199 (4.5%)
Influenza	12/199 (6.0%)
Measles	5/199 (2.5%)
Varizella (chickenpox)	74/199 (37.2%)
Medical Interventions	Number/Total (%)
Transfusion	3/200 (1.5%)
Transplantation	1/200 (0.5%)
Others	Number/Total (%)
Allergies	58/200 (29.0%)
Asthma	16/200 (8.0%)
Developmental delay	1/200 (0.5%)
Type 1 diabetes mellitus	1/200 (0.5%)
Henoch-Schoenlein purpura	1/200 (0.5%)
Immune thrombocytopenic purpura	1/200 (0.5%)
Known failure to thrive	3/200 (1.5%)
Lichen sclerosis	1/200 (0.5%)
Malignant tumor	1/200 (0.5%)
Neurodermatitis	15/200 (7.5%)
Rheumatoid arthritis	1/200 (0.5%)

[4] Vaccination status according to the recommendations of the standing committee on vaccination (STIKO) at the Robert Koch Institute (RKI), a department of the German Federal Health Agency [38], accessed at the beginning of patient recruitment on February 11th, 2016.

Supplementary Table S1D. Baseline Patient Characteristics – Recent Medical History

Medical History Within 6 Months Before IM Onset	Number/Total (%)
Fever	74/200 (37.0%)
Travelling to Europe/Middle East	130/199 (65.3%)
Travelling Far East	6/199 (3.0%)
Exposure to farm animals	24/200 (12.0%)
Antibiotics	28/200 (14.0%)
Steroids (oral, intravenous)	1/200 (0.5%)
Analgetics/antiphlogistics	63/200 (31.5%)

Supplementary Table S1E. Baseline Patient Characteristics – Signs of Primary Immunodeficiency

Signs of Primary Immunodeficiency	Number/Total (%)
Known primary immunodeficiency	1/200 (0.5%)
ELVIS – at least one criterion [5]	77/200 (38.5%)
ELVIS – one criterion	60/200 (30.0%)
ELVIS – two criteria	13/200 (6.5%)
ELVIS – three criteria	3/200 (1.5%)
ELVIS – four criteria	1/200 (0.5%)
ELVIS – unusual pathogen	8/200 (4.0%)
ELVIS – multiple localization	4/199 (2.0%)
ELVIS – relapsing course	29/200 (14.5%)
ELVIS – unusual intensity	33/200 (16.5%)
ELVIS – increased sum of minor infections	25/200 (12.5%)
GARFIELD – at least one criterion [5]	37/200 (18.5%)
GARFIELD – one criterion	35/200 (17.5%)
GARFIELD – two criteria	2/200 (1.0%)
GARFIELD – granuloma	0/200 (0.0%)
GARFIELD – autoimmunity	5/200 (2.5%)
GARFIELD – recurring fever	7/200 (3.5%)
GARFIELD – eczema, including neurodermatitis	23/200 (11.5%)
GARFIELD – lymphoproliferation	3/200 (1.5%)
GARFIELD – chronic inflammatory bowel disease	1/200 (0.5%)
ELVIS or GARFIELD – at least one criterion [5]	95/200 (47.5%)
ELVIS and GARFIELD – at least one criterion of both [5]	19/200 (9.5%)

[5] [17]

Supplementary Table S1F. Baseline Patient Characteristics – General Medical History of Family

Characteristics	Number/Total (%)
Consanguineous parents	3/200 (1.5%)
At least 1 sibling in the same household	158/200 (79.4%)
1 sibling	108/200 (54.0%)
2 siblings	36/200 (18.0%)
≥ 3 siblings	14/200 (7.0%)
Allergies	125/199 (62.8%)
Allergic asthma	15/200 (7.5%)
Infectious mononucleosis	71/199 (35.7%)
1 family member	59/199 (29.6%)
≥ 2 family members	12/199 (6.0%)
Neurodermatitis	29/199 (14.6%)
Classical autoimmune diseases	41/200 (20.5%)
Cancer	126/199 (63.3%)
Primary immunodeficiencies	1/199 (0.5%)

Suppl. Table S2. Severity of IM features at Study Visits and Study Periods

IM Feature	Early Period (EP)	Very Early Period (VEP)	Visit 1 (V1)	Visit 2 (V2)	Visit 3 (V3)
	Number/Total (%)	Number/Total (%)	Number/Total (%)	Number/Total (%)	Number/Total (%)
IM_{Clin} Features					
Fever					
S0	55/200 (27.5%)	59/199 (29.6%)	164/196 (83.7%)	190/191 (99.5%)	178/179 (99.4%)
S1	55/200 (27.5%)	55/199 (27.6%)	23/196 (11.7%)	0/191 (0.0%)	1/179 (0.6%)
S2	90/200 (45.0%)	85/199 (42.7%)	9/196 (4.6%)	1/191 (0.5%)	0/179 (0.0%)
Fatigue					
S0	8/200 (4.00%)	14/200 (7.0%)	34/200 (17.0%)	102/193 (52.8%)	147/181 (81.2%)
S1	143/200 (71.5%)	142/200 (71.0%)	154/200 (77.0%)	91/193 (47.2%)	28/181 (15.5%)
S2	42/200 (21.0%)	38/200 (19.0%)	12/200 (6.0%)	0/193(0.0%)	6/181 (3.3%)
S3	7/200 (3.5%)	6/200 (3.0%)	0/200 (0.0%)	0/193(0.0%)	0/181 (0.0%)
Lymphadenopathy					
S0	17/200 (8.5%)	20/200 (10.0%)	35/200 (17.5%)	126/192 (66.6%)	158/173 (91.3%)
S1	135/200 (67.5%)	134/200 (67.0%)	143/200 (71.5%)	66/192 (34.4%)	15/173 (8.7%)
S2	44/200 (22.0%)	43/200 (21.5%)	21/200 (10.5%)	0/192 (0.0%)	0/173 (0.0%)
S3	2/200 (1.0%)	2/200 (1.0%)	1/200 (0.5%)	0/192 (0.0%)	0/173 (0.0%)
S4	2/200 (1.0%)	1/200 (0.5%)	0/200 (0.0%)	0/192 (0.0%)	0/173 (0.0%)
Tonsillopharyngitis					

S0	17/200 (8.5%)	20/200 (10.0%)	46/200 (23.0%)	166/192 (86.5%)	159/172 (92.4%)
S1	96/200 (48.0%)	94/200 (47.0%)	105/200 (52.5%)	25/192 (13.0%)	13/172 (7.6%)
S2	63/200 (31.5%)	63/200 (31.5%)	39/200 (19.5%)	1/192 (0.5%)	0/172 (0.0%)
S3	21/200 (10.5%)	20/200 (10.0%)	7/200 (3.5%)	0/192 (0.0%)	0/172 (0.0%)
S4	3/200 (1.5%)	3/200 (1.5%)	3/200 (1.5%)	0/192(0.0%)	0/172 (0.0%)
Splenomegaly					
S0	48/195 (24.6%)	48/189 (25.4%)	51/186 (27.4%)	111/183 (60.7%)	26/37 (70.3%)
S1	90/195 (46.2%)	89/189 (47.1%)	84/186 (45.2%)	60/183(32.8%)	11/37 (29.7%)
S2	56/195 (28.7%)	51/189 (27.0%)	50/186 (26.9%)	12/183 (6.6%)	0/37 (0.0%)
S4	1/195 (0.5%)	1/189 (0.5%)	1/186 (0.5%)	0/183 (0.0%)	0/37 (0.0%)
Facial Edema					
S0	113/200 (56.5%)	114/200 (57.0%)	150/200 (75.0%)	191/194 (98.5%)	181/183 (98.9%)
S1	60/200 (30.0%)	61/200 (30.5%)	41/200 (20.5%)	3/194 (1.5%)	2/183 (1.1%)
S2	22/200 (11.0%)	21/200 (10.5%)	7/200 (3.5%)	0/194 (0.0%)	0/183 (0.0%)
S3	5/200 (2.5%)	4/200 (2.0%)	2/200 (1.0%)	0/194 (0.0%)	0/183 (0.0%)
Exanthema					
S0	145/200 (72.5%)	154/198 (77.8%)	171/197 (86.8%)	181/190 (95.3%)	179/180 (99.4%)
S1	28/200 (14.0%)	21/198 (10.6%)	9/197 (4.6%)	6/190 (3.2%)	1/180 (0.6%)
S2	21/200 (10.5%)	17/198 (8.6%)	13/197 (6.6%)	3/190 (1.6%)	0/180 (0.0%)
S3	6/200 (3.0%)	6/198 (3.0%)	4/197 (2.0%)	0/190 (0.0%)	0/180 (0.0%)
S4	0/200 (0.0%)	0/198 (0.0%)	0/197 (0.0%)	0/190 (0.0%)	0/180 (0.0%)
Bleeding and/or Treatment for Bleeding or Anemia					
S0	189/200 (94.5%)	190/200 (95.0%)	196/198 (99.0%)	192/193 (99.5%)	181/181 (100.0%)
S1	11/200 (5.5%)	10/200 (5.0%)	2/198 (1.0%)	1/193 (0.5%)	0/181 (0.0%)
S2	0/200 (0.0%)	0/200 (0.0%)	0/198 (0.0%)	0/193 (0.0%)	0/181 (0.0%)
S3	0/200 (0.0%)	0/200 (0.0%)	0/198 (0.0%)	0/193 (0.0%)	0/181 (0.0%)
S4	0/200 (0.0%)	0/200 (0.0%)	0/198 (0.0%)	0/193 (0.0%)	0/181 (0.0%)
Other Airway Symptoms					
S0	41/199 (20.6%)	43/196 (21.9%)	79/194 (40.7%)	162/191 (84.8%)	151/162 (93.2%)
S1	141/199 (70.9%)	137/196 (69.9%)	108/194 (55.7%)	28/191 (14.7%)	11/162 (6.8%)
S2	7/199 (3.5%)	7/196 (3.6%)	3/194 (1.5%)	1/191 (0.5%)	0/162 (0.0%)
S3	8/199 (4.0%)	8/196 (4.1%)	4/194 (2.1%)	0/191 (0.0%)	0/162 (0.0%)
S4	2/199 (1.0%)	1/196 (0.5%)	0/194 (0.0%)	0/191 (0.0%)	0/162 (0.0%)
Other Gastrointestinal Symptoms					
S0	57/200 (28.5%)	66/199 (33.2%)	132/198 (66.7%)	171/191 (89.5%)	170/177 (96.0%)
S1	121/200 (60.5%)	116/199 (58.3%)	57/198 (28.8%)	18/191 (9.4%)	7/177 (4.0%)
S2	10/200 (5.0%)	8/199 (4.0%)	3/198 (1.5%)	1/191 (0.5%)	0/177 (0.0%)
S3	12/200 (6.0%)	9/199 (4.5%)	6/198 (3.0%)	1/191 (0.5%)	0/177 (0.0%)
S4	0/200 (0.0%)	0/199 (0.0%)	0/198 (0.0%)	0/191 (0.0%)	0/177 (0.0%)
Urogenital Symptoms					
S0	187/199 (94.0%)	185/197 (93.9%)	192/197 (97.5%)	191/193 (99.0%)	178/180 (98.9%)
S1	10/199 (5.0%)	10/197 (5.1%)	4/197 (2.0%)	2/193 (1.0%)	2/180 (1.1%)

S2	2/199 (1.0%)	2/197 (1.0%)	1/197 (0.5%)	0/193 (0.0%)	0/180 (0.0%)
S3	0/199 (0.0%)	0/197 (0.0%)	0/197 (0.0%)	0/193 (0.0%)	0/180 (0.0%)
S4	0/199 (0.0%)	0/197 (0.0%)	0/197 (0.0%)	0/193 (0.0%)	0/180 (0.0%)
Neurological Symptoms					
S0	56/199 (28.1%)	62/196 (31.6%)	135/196 (68.9%)	172/191 (90.0%)	166/179 (92.7%)
S1	138/199 (69.3%)	129/196 (65.8%)	58/196 (29.6%)	18/191 (9.4%)	13/179 (7.3%)
S2	2/199 (1.0%)	2/196 (1.0%)	2/196 (1.0%)	0/191 (0.0%)	0/179 (0.0%)
S3	1/199 (0.5%)	1/196 (0.5%)	0/196 (0.0%)	0/191 (0.0%)	0/179 (0.0%)
S4	2/199 (1.0%)	2/196 (1.0%)	1/196 (0.5%)	1/191 (0.5%)	0/179 (0.0%)
Musculoskeletal Symptoms					
S0	103/199 (51.8%)	123/197 (62.4%)	168/197 (85.3%)	180/192 (93.8%)	174/178 (97.8%)
S1	83/199 (41.7%)	63/197 (32.0%)	24/197 (12.2%)	12/192 (6.3%)	4/178 (2.2%)
S2	11/199 (5.5%)	9/197 (4.6%)	5/197 (2.5%)	0/192 (0.0%)	1/178 (0.6%)
S3	2/199 (1.0%)	2/197 (1.0%)	0/197 (0.0%)	0/192 (0.0%)	0/178 (0.0%)
Imminent or Treatment for Hemaphagocytic Lymphohistiocytosis (HLH)					
S0	199/200 (99.5%)	199/200 (99.5%)	199/200 (99.5%)	193/194 (99.5%)	182/183 (99.5%)
S3	0/200 (0.0%)	0/200 (0.0%)	0/200 (0.0%)	1/194 (0.5%)	1/183 (0.5%)
S4	1/200 (0.5%)	1/200 (0.5%)	1/200 (0.5%)	0/194 (0.0%)	0/183 (0.0%)
Hospitalization					
S0	111/200 (55.5%)	115/200 (57.5%)	134/200 (67.0%)	194/194 (100.0%)	181/182 (99.5%)
S2	81/200 (40.5%)	81/200 (40.5%)	62/200 (31.0%)	0/194 (0.0%)	0/182 (0.0%)
S3	7/200 (3.5%)	3/200 (1.5%)	4/200 (2.0%)	0/194 (0.0%)	1/182 (0.5%)
S4	1/200 (0.5%)	1/200 (0.5%)	0/200 (0.0%)	0/194 (0.0%)	0/182 (0.0%)
IM_{Lab} Features					
Lymphocytosis					
S0	155/200 (77.5%)	164/200 (82.0%)	178/195 (91.3%)	183/185 (98.9%)	175/175 (100.0%)
S1	45/200 (22.5%)	36/200 (18.0%)	17/195 (8.7%)	2/185 (1.1%)	0/175 (0.0%)
Neutropenia					
S0	116/198 (58.6%)	151/197 (76.6%)	159/192 (82.8%)	157/183 (85.8%)	170/173 (98.3%)
S1	54/198 (27.3%)	35/197 (17.8%)	28/192 (14.6%)	22/183 (12.0%)	2/173 (1.2%)
S2	27/198 (13.6%)	10/197 (5.1%)	5/192 (2.6%)	4/183 (2.2%)	1/173 (0.6%)
S3	1/198 (0.5%)	1/197 (0.5%)	0/192 (0.0%)	0/183 (0.0%)	0/173 (0.0%)
Anemia					
S0	190/198 (96.0%)	190/197 (96.4%)	187/192 (97.4%)	182/184 (98.9%)	173/174 (99.4%)
S1	3/198 (1.5%)	3/197 (1.5%)	3/192 (1.6%)	1/184 (0.5%)	1/174 (0.6%)
S2	5/198 (2.5%)	4/197 (2.0%)	2/192 (1.0%)	1/184 (0.5%)	0/174 (0.0%)
S3	0/198 (0.0%)	0/197 (0.0%)	0/192 (0.0%)	0/184 (0.0%)	0/174 (0.0%)
S4	0/198 (0.0%)	0/197 (0.0%)	0/192 (0.0%)	0/184 (0.0%)	0/174 (0.0%)
Thrombocytopenia					
S0	148/199 (74.4%)	151/199 (75.9%)	176/194 (90.7%)	184/186 (98.9%)	173/175 (98.9%)
S1	50/199 (25.1%)	47/199 (23.6%)	17/194 (8.8%)	1/186 (0.5%)	2/175 (1.1%)
S2	0/199 (0.0%)	0/199 (0.0%)	0/194 (0.0%)	0/186 (0.0%)	0/175 (0.0%)

S3	0/199 (0.0%)	0/199 (0.0%)	0/194 (0.0%)	0/186 (0.0%)	0/175 (0.0%)
S4	1/199 (0.5%)	1/199 (0.5%)	1/194 (0.5%)	1/186 (0.5%)	0/175 (0.0%)
Hyperferritinemia					
S0	124/200 (62.0%)	122/192 (63.5%)	129/195 (66.2%)	180/186 (96.8%)	175/176 (99.4%)
S1	56/200 (28.0%)	51/192 (26.6%)	50/195 (25.6%)	5/186 (2.7%)	0/176 (0.0%)
S2	15/200 (7.5%)	14/192 (7.3%)	14/195 (7.2%)	1/186 (0.5%)	1/176 (0.6%)
S3	4/200 (2.0%)	4/192 (2.1%)	1/195 (0.5%)	0/186 (0.0%)	0/176 (0.0%)
S4	1/200 (0.5%)	1/192 (0.5%)	1/195 (0.5%)	0/186 (0.0%)	0/176 (0.0%)
Hepatitis or Cholangitis					
S0	70/200 (35.0%)	74/200 (37.0%)	86/196 (43.9%)	155/186 (83.3%)	174/174 (100.0%)
S1	105/200 (52.5%)	101/200 (50.5%)	97/196 (49.5%)	31/186 (16.7%)	0/174 (0.0%)
S2	19/200 (9.5%)	19/200 (9.5%)	10/196 (5.1%)	0/186 (0.0%)	0/174 (0.0%)
S3	6/200 (3.0%)	6/200 (3.0%)	3/196 (1.5%)	0/186 (0.0%)	0/174 (0.0%)
S4	0/200 (0.0%)	0/200 (0.0%)	0/196 (0.0%)	0/186 (0.0%)	0/174 (0.0%)
Nephropathy					
S0	197/199 (99.0%)	194/195 (99.5%)	193/194 (99.5%)	186/186 (100.0%)	173/173 (100.0%)
S1	1/199 (0.5%)	0/195 (0.0%)	0/194(0.0%)	0/186 (0.0%)	0/173 (0.0%)
S2	1/199 (0.5%)	1/195 (0.5%)	1/194 (0.5%)	0/186 (0.0%)	0/173 (0.0%)
S3	0/199 (0.0%)	0/195 (0.0%)	0/194 (0.0%)	0/186 (0.0%)	0/173 (0.0%)
Elevation of C-reactive Protein					
S0	83/200 (41.5%)	86/200 (43.0%)	123/196 (62.8%)	180/187 (96.3%)	175/175 (100.0%)
S1	106/200 (53.0%)	105/200 (52.5%)	72/196 (36.7%)	7/187 (3.7%)	0/175 (0.0%)
S2	11/200 (5.5%)	9/200 (4.5%)	1/196 (0.5%)	0/187 (0.0%)	0/175 (0.0%)
S3	0/200 (0.0%)	0/200 (0.0%)	0/196 (0.0%)	0/187 (0.0%)	0/175 (0.0%)

FIGURE LEGENDS

Figure 1 – Study Setting with Number of Participants (A), Study Visits, and Study Periods (B).

(A) Two hundred patients were recruited, of which 194 were seen at visit 2 (V2) and 183 at visit 3 (V3), with two patients not seen at V2 but again at V3 and another four dropping out before V2. (B) The X-axis depicts the days after onset (DAO) of IM from day 0 up to day 349 when the last patient was seen for V3. V1 was scheduled up to 28 DAO, V2 23-52 DAO, and V3 142-349 DAO. Time periods were defined as medical history period (HP) as the time period before T_{onset} , i.e., 0 DAO, the very early period (VEP) from IM onset (T_{onset}) until and including V1 and the early period (EP) from T_{onset} until and including V2.

Figure 2 – Virological IM Features

Alluvial plots of virological features of IM (IM_{vir}). The first row shows the results of the chemiluminescent microparticle immunoassay (CMIA) for EBNA1 IgG, EBV VCA IgG, and EBV VCA IgM. The second row shows the PCR results for detecting EBV DNA in cell fraction, in plasma, and in oral washes. The third and fourth rows show the Immunoblot results for EBNA1 IgG, EBV VCAp18 IgG, EBV BZLF1 IgG, EBV VCAp23 IgG, EBV EAp138 IgG, and EBV EAp54 IgG. Red depicts a negative result, yellow is an intermediate, and green is a positive result of the respective method. Grey indicates missing data. The bands between the stacked columns show the development of the test results. CMIA at V1, V2, and V3 detected VCA IgM in 93.5%, 83.2%, and 26.6%, VCA IgG in 81.5%, 91.9%, and 99.4%, and EBNA-1 IgG in 2.5%, 2.7% and 86.5% cases, respectively, indicating negative VCA IgM and/or IgG at V1, negative EBNA-1 IgG at V3, and persisting VCA IgM at V3 in some cases as expected. Immunoblots at V1, V2, and V3 showed IgG against VCAp18 in 9.6%, 15.1% and 98.9% against EAp54 in 76.6%, 77.8% and 48.3%, against EAp138 in 33.5%, 31.4% and 41.6% patients, and against at least one EA in 80.7%, 81.6% and 60.7% respectively, demonstrating early VCAp18 IgG and late EA IgG in a significant number of patients. PCR at V1, V2, and V3 revealed EBV_{oral} in 86.5%, 66.7% and 38.2%, EBV_{cells} in 91.8%, 55.1% and 42.1% and EBV_{plasma} in 39.3%, 0.0% and 0.6% patients, respectively, with detectable EBV DNA in recovered cases as expected. The highest viral load at V1, V2, and V3 were 38,100.0 Geq/10⁵, 8,190.0 Geq/10⁵, and 2,330.0 Geq/10⁵ for EBV_{cells} , and 130,000.0 IU/ml, 0 IU/ml and 530.0 IU/ml for EBV_{plasma} , indicating that very high viral load in peripheral blood is short-lived as described [8].

Figure 3 – Main Clinical Outcomes

Summary of outcomes measured for the very early period (VEP, grey), the early period (EP, grey), and at the visits 1 – 3 (colored). The severity of all symptoms, according to the IMMUC score (A), includes clinical and laboratory symptoms. The violin plot of the complexity score (B) shows the number of observed clinical and laboratory symptoms. Protraction (C) indicates if patients had symptoms until and including V1 (P0), V2 (P1), or V3 (P2).

Figure 4 – Results of the Visit-Dependent Analyses

Multivariable logistic regression models were used to model the effect of each visit-dependent variable for protraction (P2-IM) (A) and fatigue at V3 (P2-fatigue) (B). A separate model was estimated for each predictor variable, with sex and age as additional covariables. Each subplot shows how the log OR (black line) changes depending on the days after the onset (DAO) of IM symptoms. The dashed lines show the pointwise 95%-confidence band. A log OR of 0 is equivalent to an OR of 1. Thus, whenever the zero line (grey) is not included in the 95%-confidence band, the OR is significantly different from 1. The DAO where the zero line intersects the boundary of the 95%-confidence band is marked by a red cross, with the respective DAO in parenthesis. The blue rug shows when the respective (multiple) measurements were taken. The respective AUC of each model and the number of measurements included in the model is shown in the top left corner of each plot.

Figure 5 – Results of the Period-Dependent Analyses

Forest plot of the significant results of the period-dependent analyses. Multivariable logistic regression models were used to model the effect of each visit-dependent variable for protraction (P2-IM) (A) and fatigue at V3 (P2-fatigue) (B). A separate model was estimated for each predictor variable, with sex and age as additional covariables. The number of observations and AUC are provided in adjacent columns. HP indicates the medical history period prior to T_{onset} , VEP the very early period from T_{onset} up to and including V1, and EP the early period from T_{onset} up to and including V2.

SUPPLEMENTARY FIGURE LEGENDS

Supplementary Figure S1 – Clinical and Laboratory IMMUC Severity Scores

The relative frequency of the severity of clinical (IM_{Clin}) (A) and laboratory symptoms (IM_{Lab}) (B) for the very early period (VEP, grey), the early period (EP, grey), and the visits 1 – 3 (colored) are shown.

Supplementary Figure S2 – Clinical and Laboratory IMMUC Complexity Scores

The complexity of clinical (IM_{Clin}) (A) and laboratory symptoms (IM_{Lab}) (B) during the very early period (VEP, grey), the early period (EP, grey), and the visits 1 – 3 (colored) are shown.

Supplementary Figure S3 – IMMUC Severity Scores of Each Symptom

The severity of individual symptoms for the very early period (VEP, A), the early period (EP, B), and at the visits V1 (C), V2 (D), and V3 (E) are shown. n/N (%) indicates the number of patients with the symptom relative to the number of patients where the respective symptom was assessed.


REFERENCES

1. Leung, A.K.C., J.M. Lam, and B. Barankin, *Infectious Mononucleosis: An Updated Review*. *Curr Pediatr Rev*, 2024. **20**(3): p. 305-322.
2. Marsh, R.A., *Epstein-Barr virus and hemophagocytic lymphohistiocytosis*. *Front Immunol*, 2017. **8**: p. 1902.
3. Damania, B. and C. Munz, *Immunodeficiencies that predispose to pathologies by human oncogenic gamma-herpesviruses*. *FEMS Microbiol Rev*, 2019. **43**(2): p. 181-192.
4. Pedersen, M., et al., *Predictors of chronic fatigue in adolescents six months after acute Epstein-Barr virus infection: A prospective cohort study*. *Brain Behav Immun*, 2019. **75**: p. 94-100.
5. Conroy, K.E., M.F. Islam, and L.A. Jason, *Evaluating case diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): toward an empirical case definition*. *Disabil Rehabil*, 2022: p. 1-8.
6. CDC. *Myalgic Encephalomyelitis/Chronic Fatigue Syndrome*. 2021 [cited 2023 2023/11/08]; Available from: <https://www.cdc.gov/me-cfs/symptoms-diagnosis/symptoms.html>.
7. Balfour, H.H., Jr., et al., *A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis*. *J Infect Dis*, 2005. **192**(9): p. 1505-12.
8. Balfour, H.H., Jr., et al., *Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students*. *J Infect Dis*, 2013. **207**(1): p. 80-8.
9. Odame, J., et al., *Correlates of illness severity in infectious mononucleosis*. *Can J Infect Dis Med Microbiol*, 2014. **25**(5): p. 277-80.
10. Buchwald, D.S., et al., *Acute infectious mononucleosis: characteristics of patients who report failure to recover*. *Am J Med*, 2000. **109**(7): p. 531-7.
11. Wemel, A.C., et al., *Severe infectious mononucleosis in immunocompetent adults*. *Med Mal Infect*, 2017. **47**(8): p. 540-545.


12. Aslan, N., et al., *Severity of acute infectious mononucleosis correlates with cross-reactive Influenza CD8 T-Cell receptor repertoires*. mBio, 2017. **8**(6).
13. Katz, B.Z., et al., *A validated scale for assessing the severity of acute infectious mononucleosis*. J Pediatr, 2019. **209**: p. 130-133.
14. Jason, L.A., et al., *Risks for developing myalgic encephalomyelitis/chronic fatigue syndrome in college students following infectious mononucleosis: A prospective cohort study*. Clin Infect Dis, 2021. **73**(11): p. e3740-e3746.
15. Jason, L.A., et al., *Predictors for developing severe myalgic encephalomyelitis/chronic fatigue syndrome following infectious mononucleosis*. J Rehabil Ther, 2022. **4**(1): p. 1-5.
16. Team, R.C. *The R project for statistical computing*. 2022; Available from: <https://www.r-project.org>.
17. Ehl, S., *Immundefekte – neue Entwicklungen, die Kinderärzte kennen sollten*. Monatsschr Kinderheilkd 2023. **171**: p. 698–705.
18. Hocqueloux, L., et al., *The high burden of hospitalizations for primary EBV infection: a 6-year prospective survey in a French hospital*. Clin Microbiol Infect, 2015. **21**(11): p. 1041 e1-7.
19. Pheby, D.F.H., et al., *The Role of Prevention in Reducing the Economic Impact of ME/CFS in Europe: A Report from the Socioeconomics Working Group of the European Network on ME/CFS (EUROMENE)*. Medicina (Kaunas), 2021. **57**(4).
20. Cervia, C., et al., *Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome*. Nat Commun, 2022. **13**(1): p. 446.
21. Katz, B.Z., et al., *Autonomic symptoms at baseline and following infectious mononucleosis in a prospective cohort of adolescents*. Arch Pediatr Adolesc Med, 2011. **165**(8): p. 765-6.
22. Lutz, L., et al., *Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome*. Biomolecules, 2021. **11**(9).
23. Guillevin, L., *Infections in vasculitis*. Best Pract Res Clin Rheumatol, 2013. **27**(1): p. 19-31.
24. Yang, Y. and F. Gao, *Clinical characteristics of primary and reactivated Epstein-Barr virus infection in children*. J Med Virol, 2020.
25. Ciccarese, G., et al., *Dermatological manifestations of Epstein-Barr virus systemic infection: a case report and literature review*. Int J Dermatol, 2020. **59**(10): p. 1202-1209.
26. Balfour, H.H., Jr., S.K. Dunmire, and K.A. Hogquist, *Infectious mononucleosis*. Clin Transl Immunology, 2015. **4**(2): p. e33.
27. Geris, J.M., et al., *Rapid antibody responses to Epstein-Barr virus correlate with reduced severity of primary infection*. J Clin Virol, 2022. **155**: p. 105267.
28. Karsten, C.B., et al., *Evolution of functional antibodies following acute Epstein-Barr virus infection*. PLoS Pathog, 2022. **18**(9): p. e1010738.
29. Donzel, M., et al., *Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France*. EClinicalMedicine, 2022. **54**: p. 101674.
30. Soldan, S.S. and P.M. Lieberman, *Epstein-Barr virus and multiple sclerosis*. Nat Rev Microbiol, 2023. **21**(1): p. 51-64.
31. Harrell, F.E.J., *Regression modeling strategies*. 2 ed. 2015: Springer Cham.
32. Whitehead, J., *Sample size calculations for ordered categorical data*. Stat Med, 1993. **12**(24): p. 2257-71.
33. Hesse, V., et al., *Längsschnittstudie des aktuellen Wachstums 0- bis 6-jähriger deutscher Kinder: Teil 1*. Monatsschr Kinderheilkd, 2016. **164**: p. 478-496.
34. Kromeyer-Hauschild, K., et al., *Perzentile für den Body-mass-Index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben*. Monatsschr Kinderheilkd, 2001. **149**: p. 807-818.
35. Hemmelmann, C., et al., *Perzentilen des Body-Mass-Index auch für 18- bis 80-Jährige? Daten der Nationalen Verzehrsstudie II [Percentiles of body mass index of*


- 18-80-year-old German adults based on data from the Second National Nutrition Survey*. Dtsch Med Wochenschr, 2010. **135**(17): p. 848-852.
36. Thomas, L., *Labor und Diagnose: Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik*. 7. Auflage ed. 2007: Th-Books.
 37. RKI, *Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise zu Impfungen für Patienten mit Immundefizienz*. 2005, Robert Koch-Institut (RKI).
 38. RKI, *Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2015*. 2015, Robert Koch-Institut (RKI).




A)






B)














Supplementary Figure S1



A)



B)

